Guidance for Industry: Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and New Variant Creutzfeldt-Jakob Disease (nvCJD) by Blood and Blood Products; Availability

Краткое содержание

The Food and Drug Administration (FDA) is announcing the availability of a guidance document entitled ``Guidance for Industry: Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and New Variant Creutzfeldt-Jakob Disease (nvCJD) by Blood and Blood Products.'' The guidance document is intended to provide recommendations to all registered blood and plasma establishments and all establishments engaged in manufacturing plasma derivatives. The guidance document is intended to replace the FDA guidance entitled ``Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt- Jakob Disease (CJD) by Blood and Blood Products'' issued on December 11, 1996.